Related Experiment Videos
5-(1-piperazinyl)-1H-1,2,4-triazol-3-amines as antihypertensive agents
W E Meyer1, A S Tomcufcik, P S Chan
1American Cyanamid Company, Medical Research Division, Lederle Laboratories, Pearl River, New York 10965.
Journal of Medicinal Chemistry
|March 1, 1989
Summary
Researchers synthesized novel piperazinyl-triolamine compounds for hypertension treatment. Compound 8 showed promising antihypertensive effects by suggesting ganglionic blocking activity in rats and dogs.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cardiovascular Research
Background:
- Hypertension remains a significant global health challenge.
- Development of novel antihypertensive agents is crucial.
Purpose of the Study:
- To synthesize and screen novel 5-(1-piperazinyl)-1H-1,2,4-triazol-3-amine derivatives for antihypertensive and diuretic activity.
- To elucidate the mechanism of action for the most potent compound.
Main Methods:
- Synthesis of a series of piperazinyl-triolamine compounds.
- In vivo screening for antihypertensive and diuretic effects in spontaneously hypertensive rats (SHR).
- Pharmacological studies in SHR and conscious renal hypertensive dogs to determine the mechanism of action.
Main Results:
- One compound, 5-[4-[(3-chlorophenyl)methyl]-1-piperazinyl]-1H-1,2,4-triazol-3-amine (8), exhibited significant antihypertensive activity.
- Studies in SHR indicated that compound 8 possesses ganglionic blocking activity.
- Short-lived antihypertensive effects were also observed in renal hypertensive dogs.
Conclusions:
- The synthesized piperazinyl-triolamine derivatives represent a potential new class of antihypertensive agents.
- Compound 8's mechanism of action involves ganglionic blockade.
- Further investigation is warranted to explore the therapeutic potential of these compounds.